Alzheimer's Symptoms May Surface in Your 20s, Study Finds
Alzheimer's symptoms and changes in cognitive function typically start to appear after age 65.
A new study published in Lancet Regional Health-Americas finds that Alzheimer's symptoms can present much earlier than thought, as early as the mid-20s.
Experts say that in addition to staying active, eating healthy, avoiding tobacco, and limiting alcohol, it's a good idea to try to use your brain "vigorously" to stay sharp.
When you close your eyes and think about Alzheimer's disease, you're probably conjuring up an image of an older person. That makes sense, because the symptoms usually start to rear their ugly heads after age 65. But new research suggests that the devastating disease may actually influence a person's cognitive function decades before they're actually diagnosed.
The groundbreaking study, which was published in the journal Lancet Regional Health – Americas, is raising a lot of questions about early biomarkers for Alzheimer's disease—and how to keep your brain healthy, starting from a younger age.
Here's what the study found, plus what neurologists want you to keep in mind when digesting the information.
Meet the experts: Clifford Segil, DO, is a neurologist at Providence Saint John's Health Center in Santa Monica, CA; Amit Sachdev, MD, MS, is the medical director in the Department of Neurology at Michigan State University.
For the study, researchers analyzed data from Waves IV and V of the National Longitudinal Study of Adolescent to Adult Health, which is a long-term health study that has tracked teens since the mid-90s.
The researchers did a slew of in-home interviews, cognitive tests, and physical exams, and collected blood samples from thousands of participants in their 20s and 30s. Ultimately, 1,112 study participants who did in-home interviews were given cognitive tasks like immediate word recall, delayed word recall, and backward digit span. They also provided a sample for genetic testing. The researchers then tied those scores to Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) scores in 529 people.
The researchers discovered that certain risk factors and biomarkers linked to Alzheimer's disease may influence a person's cognitive function starting in their mid-20s and continuing onwards. 'Key risk factors for Alzheimer's disease are linked to cognitive function as early as ages 24–44, highlighting the need for early prevention in the US,' the researchers wrote in the conclusion.
The study focused on a few different factors, including the CAIDE score. The list included things like a person's age, education, sex, systolic blood pressure (the top number in a blood pressure reading), body mass index, cholesterol, physical activity, and the gene variant apolipoprotein E ε4 allele (APOE ε4), a genetic risk factor for Alzheimer's disease.
The researchers also discovered that ATN (amyloid, tau, neurodegeneration), and immune biomarkers linked to Alzheimer's disease may be present and related to cognition in people in their 40s and younger.
Sort of. 'When I see younger patients concerned with getting dementia when they are elderly, I 'risk stratify' and do the same tests I would do in an octogenerian concerned they have dementia,' says Clifford Segil, DO, a neurologist at Providence Saint John's Health Center in Santa Monica, CA.
That means doing blood tests to look for reversible causes of memory loss—including thyroid tests and checking vitamin levels like B12. 'I would also obtain a structural picture of their brain to see if they have had silent strokes or atrophy,' Dr. Segil says.
The only actual available "test" for Alzheimer's disease in younger people would be to check someone's APOE 4 levels, which is considered the strongest genetic risk factor for Alzheimer's disease, Dr. Segil says. 'But this [test] being positive in a young patient would be challenging to say has any clinical significance,' he adds.
There are a few things you can do right now to make sure you have the healthiest brain as you get holder. Aside from eating a healthy diet, staying active, avoiding tobacco, and limiting your alcohol consumption, it's a good idea to 'vigorously' use your brain, says Amit Sachdev, MD, MS, medical director in the Department of Neurology at Michigan State University.
'This is best achieved through self-investment in education but also through socialization and human interaction,' he says. 'Working on finding and cultivating new friends and interests in youth helps to develop those old friendships that are so important later in life.'
Dr. Segil also recommends keeping your body and mind busy to maintain your brain health.
Ultimately, if you're concerned about your dementia risk or if you have a family history of the disease, check in with your primary care physician, who should be able to offer some personalized guidance.
You Might Also Like
Can Apple Cider Vinegar Lead to Weight Loss?
Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Rates of dementia are lower in people who eat this specific diet, research shows
Certain foods may feed the brain better than others. New research presented this week at NUTRITION 2025, the annual meeting of the American Society for Nutrition in Orlando, Florida, found that the MIND diet is particularly beneficial for cognitive health. People who followed the MIND eating plan — which stands for Mediterranean-DASH Intervention for Neurodegenerative Delay — were "significantly less likely" to develop Alzheimer's disease or other forms of dementia, according to a press release from the American Society for Nutrition. Brain And Memory Are Boosted By Eating One Particular Diet, Study Finds MIND is a hybrid of the Mediterranean diet and the DASH diet (Dietary Approaches to Stop Hypertension), the latter of which is designed to reduce blood pressure. The diet focuses on "brain-healthy foods" like leafy green vegetables, berries, nuts and olive oil. Read On The Fox News App "The MIND diet is unique as the first eating plan focused on foods to specifically improve and support cognitive health," Lauren Harris-Pincus, registered dietitian nutritionist and founder of and author of "The Everything Easy Pre-Diabetes Cookbook," told Fox News Digital. The plant-focused MIND diet highlights 10 types of food, including berries, leafy greens, veggies, whole grains, nuts and seeds, beans, legumes, seafood, poultry and olive oil, according to Harris-Pincus, who was not involved in the research. Red Meat Could Raise Dementia Risk, Researchers Claim, Yet Some Doctors Have Questions "These focus foods contain nutrients that play a critical role in supporting brain health, including flavonoids, carotenoids, B vitamins, omega-3 fatty acids (especially DHA), choline, and minerals like magnesium, potassium and calcium," she said. "The diet also suggests limiting foods such as pastries, refined sugar, red meat, cheese, fried foods, fast food, and butter or margarine." Researchers from the University of Hawaii analyzed data from nearly 93,000 U.S. adults who reported their dietary habits during the 1990s as part of the Multiethnic Cohort Study. At the start of the study, participants ranged in age from 45 to 75. In analyzing which participants developed Alzheimer's or other dementias in later years, the MIND eating plan performed better than other healthy diets in terms of reducing dementia risk, with benefits seen among both younger and older groups. Click Here To Sign Up For Our Health Newsletter Those who followed the diet were shown to have an overall 9% reduced risk of dementia, and some groups — African American, Latino and White participants — showed a 13% lower risk. Asian-Americans and native Hawaiians did not show as pronounced of a risk reduction. The longer people adhered to the diet, the greater the reduction of risk. Those who followed the plan over a 10-year period had a 25% lower risk compared to those who didn't stick with it. "Our study findings confirm that healthy dietary patterns in mid to late life and their improvement over time may prevent Alzheimer's and related dementias," said Song-Yi Park, PhD, associate professor at the University of Hawaii at Manoa, in the release. For more Health articles, visit "This suggests that it is never too late to adopt a healthy diet to prevent dementia."Original article source: Rates of dementia are lower in people who eat this specific diet, research shows
Yahoo
6 hours ago
- Yahoo
HUNDREDS OF HEALTH PROFESSIONALS, ATTORNEYS, ENVIRONMENTALISTS AND PATIENTS SET TO CONVENE AT THE ANNUAL CIRSx CONFERENCE 2025 TO ADDRESS MOLD ILLNESS, WHICH AFFECTS MILLIONS OF AMERICANS
LOS ANGELES, June 3, 2025 /PRNewswire/ -- The organizers of the Surviving Mold-CIRSx Conference 2025 is happy to announce Dr. Dale Bredesen as its keynote speaker, set to be held on June 6-8, 2025 at the Omni Tempe, located on the campus of Arizonia State University. He is an internationally-recognized expert in neurodegenerative diseases like Alzheimer's. He believes that the disease is not only preventable but reversible! He will address the topic of "A Unifying Theory of Neurodegeneration: The Roles of Environmental Exposure," discussing a direct link to mold exposure and Alzheimer's disease. More of his research on this topic can be found in his New York Times Best Seller, "The End of Alzheimer's." The international conference will bring together hundreds of health professionals, lawyers and legal experts, environmentalists, patients and survivors to discuss the latest science and research related to Chronic Inflammatory Response Syndrome (CIRS) – that is, mold illness and exposure -- which debilitates the health of millions each year. CIRS is a multisystem illness affecting many areas of the body. Every year, mold exposure affects the health of millions of Americans – kids, teens and adults -- with symptoms that include chronic fatigue and pain, watery eyes, headaches, respiratory issues, brain fog, irritability and sleep problems – just to name a few. Oftentimes, these symptoms can often lead to patients being misdiagnosed for other disorders like lupus, rheumatoid arthritis, Sjogren's syndrome, chronic fatigue syndrome, IBS, fibromyalgia, multiple sclerosis (MS), chronic regional pain syndrome and many other illnesses. "The Surviving Mold-CIRSx Conference brings together some of the world's top experts who will be teaching and presenting from the basic sciences to the most cutting-edge mold discoveries. This conference is the best place to meet practitioners in diverse fields and join the CIRS family," said Dr. McMahon, one of the co-founders of CIRSx, which hosts the annual conference. A pediatrician and medical expert, specializing in the field of CIRS in kids and adults, Dr. McMahon is considered one of the top CIRS specialists in the world. Throughout his career, he's evaluated approximately 2,000 patients for CIRS from 48 states and 21 countries. And he's been involved in more than 100 disability, workers compensation and personal injury cases, testifying in 10 states as well as Canada, England and the Bahamas. Dr. McMahon was recently tapped at the medical director of MoldCo, the first digital health platform dedicated to treating mold toxicity. During the conference, Dr. McMahon will speak on the topic, "Using Data to Restore Truth in the Courtroom," Plus, Dr. McMahon's mentor, Dr. Ritchie Shoemaker, THE pioneer and global expert on CIRS, will discuss a topic, which hits close to home – that is, "Brain Injury in CIRS: From Specific Causation to a Unique Transcriptomic Fingerprint in Parkinson's Disease." In addition, the conference will also offer 18.75 of Continuing Medical Education (CME) to its attendees. This conference has been approved by My CE Course for 18.75 hours credit in Category 1 of the Physician's Recognition Award of the American Medical Association. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the My CE Course (MyCE) through the joint providership of MyCE and The Learning Center. MyCE is accredited to provide continuing medical education for physicians, physician assistants and nurses. Other highlights of the conference include ED Talks, presented by its sponsors Air Oasis®, MoldCo and Alovéa. These brands will delve into the critical role it plays in the CIRS community in shaping consumer perception, establishing consumer confidence and driving business success. These talks will take attendees behind each of the brands' logo and tagline to share its mission, values and unique story of the company. Ariana Thacker, founder and CEO of MoldCo, will share her own journey in battling mold toxicity. For more information about the conference, visit ABOUT CIRSx, hosts of the Surviving Mold-CIRSx Conference is the leading resource in treating, educating and serving those with Chronic Inflammatory Response Syndrome (CIRS). Every year, hundreds of health professionals, lawyers and legal experts, environmentalists, patients and CIRS survivors gather at an annual conference, hosted by CIRSx to discuss the latest science and research on CIRS and other inflammatory illnesses. At the forefront of health innovation, CIRSx is dedicated to creating and refining standards that stay on the cutting edge of treating CIRS, using an evidence-based approach. Its mission is to transform multiple industries, revolutionizing their approaches toward CIRS and other environmentally-related health challenges. The heart of CIRSx is the compassionate healers and dedicated helpers. These professionals are not just experts in their field, but are also deeply committed to providing personalized care and support to those affected by CIRS. For more information about the conference, visit ABOUT SCOTT MCMAHON | pediatrician, medical expert and co-founder of CIRSxDr. McMahon is one of the leading voices on advancing the science to treat, educate and serve those suffering with CIRS. He received his medical degree from Creighton University and completed his pediatric residency at Duke University Medical Center. He has published over a dozen peer-reviewed papers on mold illness and is a recognized expert witness in mold-related court cases across the United States, Canada, Europe and the Bahamas. Dr. McMahon is also the host of MEDICINE AND MIRACLES, which integrates medical expertise with spiritual healing and offers a unique look at health and recovery through a faith-based perspective. MEDICINE AND MIRACLES can be found on digital platforms, including Spotify, Audible, iHeart Radio and Amazon Podcast. Learn more at He resides in Roswell, New Mexico, with his wife Mary and a blended family of eight children. View original content to download multimedia: SOURCE Dr. Scott McMahon of Whole World Health Care Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Associated Press
11 hours ago
- Associated Press
Bioxytran's Groundbreaking Stroke & Alzheimer's Tech Gains Validation That Measures Oxygenation Uptake During Strokes
Mongolian Gerbil Research Unlocks Critical Insights for Ischemic Stroke and Neurodegenerative Disease Treatments BOSTON, MASSACHUSETTS, June 03, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the 'Company'), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer's disease, announced that Bioxtran's Science Advisor Prof. Avraham Mayevsky's book titled The Mongolian Gerbil Brain: Mitochondrial Function, Vasculature, and Pathophysiological States was published by a publishing house, Springer. It is available by eBook or Hardcover. The publication serves as a scientific cornerstone for Bioxytran's clinical development program of the universal oxygen carrier (UOC) in ischemic stroke and Alzheimer's disease, and is directly tied to the use of the MDX Viewer as an analytical method to detect a brain regions response to the addition of a UOC. The device has FDA approval to measure tissue oxygenation. Bioxytran is pioneering a transformative approach to treating ischemic stroke and neurodegenerative disease. The UOC is capable of replacing hyperbaric oxygen treatment (HBOT) by efficiently delivering therapeutic type of oxygen at the cellular level versus a charged version of oxygen prevalent in HBOT treatment called reactive oxygen species (ROS). This breakthrough is powered by the MDX viewer that provides real-time metabolic insights – a crucial element of Bioxytran's regulatory approach. The Mongolian gerbil brain is special in that it lacks the vasculature compensatory mechanisms that can deal with decreased blood flow in the event of a stroke. Since the blood vessels in the Mongolian gerbil brain have no coping mechanism it makes them ideal in studying stroke pathophysiology. The research compiled in this publication further validates Bioxytran's scientific and clinical approach, positioning the company on the cutting edge of advancements in brain health and neuroprotective treatments. 'This research is paving the way for substantial advances in the understanding of the pathology of stroke and other neurodegenerative diseases, said Avraham Mayevsky, Member of Bioxytran's Medical Advisory Board. 'One of the biggest challenges in in clinical trials is determining the efficacy of a drug. This gerbil brain model has great predictive value in ischemic stroke and Alzheimer's disease. The gerbil model coupled with the MDX Viewer will provide us amazing insight in the pathogenesis of stroke and neurodegenerative diseases. Over 60 years went toward the development of the book which highlights a model of how brain anomalies are detected using this device.' About Bioxytran, Inc. Bioxytran, Inc. is at the forefront of developing complex carbohydrate-based therapeutics to address critical unmet medical needs in its three core platform technologies. These include virology, cancer metastasis, and oxygen transport. In addition to ProLectin-M, Bioxytran is advancing programs for pulmonary fibrosis and stroke treatment. When utilized by paramedics at the time of diagnosis BXT-25 has the possibility of reducing what is known as the time until needle by over 90%. For more information, visit Investor Relations Michael Sheikh 509-991-0245 [email protected] Forward-Looking Statements This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words 'believe,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'plan,' and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran's actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.